Investment Fund Brandon Capital Successfully Closes Sixth Edition with Aggregate Capital of over A$439 Million
Brandon BioCatalyst Fund Six (BB6) Closes at A$439 Million
Brandon Capital's sixth fund, the Brandon BioCatalyst Fund Six (BB6), has reached a total of A$439 million, marking it as the firm's largest fund to date. The BB6 focuses on investing in emerging biomedical technologies that aim to translate scientific discoveries into high-growth companies dedicated to improving human health.
The fund has attracted investments from several notable backers, including Hesta, Host Plus, CSL, QIC, the Western Australia Government, and the National Reconstruction Fund Corporation (NRFC). The NRFC's investment of A$150 million in BB6 signifies a commitment to fostering local commercialization capabilities in the biomedical sector.
With the close of BB6, Brandon Capital has raised over A$1 billion in total.
The BB6 fund has made key investments in several promising companies. These include AdvanCell, specialising in radiopharmaceuticals; PolyActiva, developing biodegradable glaucoma implants; Myricx Bio, working on antibody-drug conjugates; and CatalYm, focusing on oncology immunotherapy.
The contributions BB6 has made to the Australian manufacturing sector and global collaboration are significant. The fund supports over 30 companies and more than 270 skilled jobs in Australia, strengthening the life sciences manufacturing workforce. It also enhances Australia's sovereign medical manufacturing capacity by enabling local commercialization instead of innovation being lost offshore.
Furthermore, BB6 facilitates global collaboration by operating offices in San Francisco and London, offering portfolio companies international market access, and linking overseas businesses with Australia’s clinical trial and research infrastructure.
The fund has accelerated the translation of world-class Australian biomedical research into high-growth companies. Recent successes include FDA approvals for therapies from George Medicines and EBR Systems, as well as Q-Sera's approval in Japan.
In summary, BB6's investments foster the growth of innovative biomedical companies, strengthen Australia's manufacturing sector by creating skilled jobs and capacity, and leverage global collaborations to bring Australian medical breakthroughs to international markets. The NRFC's investment in BB6 underscores their belief in Brandon Capital's ability to drive breakthrough biomedical innovations.
[1] Brandon Capital Press Release
[2] Australian Financial Review
[3] Life Sciences Hub Wales
[4] Investor Daily
[5] BioSpectrum Asia
Venture capital from sources like Hesta, Host Plus, CSL, QIC, the Western Australia Government, and the National Reconstruction Fund Corporation (NRFC) has contributed to the A$439 million growth of Brandon BioCatalyst Fund Six (BB6), which focuses on science and technology-driven growth companies in the biomedical sector. With strategic investments in companies such as AdvanCell, PolyActiva, Myricx Bio, and CatalYm, BB6 promotes innovation, creates skilled jobs, and strengthens Australia's manufacturing sector and global collaborative opportunities in the life sciences industry.
